UK pathology rises to growing market challenges but tighter performance called for
This article was originally published in Clinica
Local inconsistencies in UK pathology service quality and costs have overshadowed otherwise solid praise for the way the diagnostics industry is meeting the significant rise in demand, the Healthcare Commission's national report for 2005-06, published this week, shows.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.